Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 19

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 19
---
 to the Selling Shareholder
prior to the date of termination. We or the Selling Shareholder may also terminate the Purchase Agreement at the close of business on
the one year anniversary of the signing of the Purchase Agreement or thereafter, in the event the Commencement Date shall not have occurred
prior to such one year anniversary due to our failure to satisfy the conditions precedent to commencement. We and the Selling Shareholder
may also terminate the Purchase Agreement at any time by mutual written consent. No termination of the Purchase Agreement by us or by
the Selling Shareholder will affect any of our respective rights and obligations under (i) the Purchase Agreement with respect to any
pending Purchase, and both we and the Selling Shareholder have agreed to complete our respective obligations with respect to any such
pending Purchase under the Purchase Agreement, and (ii) the Registration Rights Agreement, which shall survive any termination of the
Purchase Agreement. Further, no termination of the Purchase Agreement will be deemed to release us or the Selling Shareholder from any
liability for intentional misrepresentation or willful breach of the Purchase Agreement, the Registration Rights Agreement or any other
related transaction documents.

Dilutive Issuances and Purchase Price Adjustment

For as long as the Selling
Shareholder owns any of our Depositary Shares, if within three trading days immediately following a Purchase Date, we make certain issues
of our securities and such securities are issued at prices, or the New Issuance Price, less than the prices to be paid by the Selling
Shareholder in such Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, the purchase price for such applicable Fixed Purchase,
VWAP Purchase or Additional VWAP Purchase would be reduced to the New Issuance Price, subject to the terms and conditions set forth in
the Purchase Agreement.

| 15 |

No Short-Selling or Hedging

The Selling Shareholder has
agreed that neither it nor any entity managed or controlled by it will engage in, directly or indirectly, any (A) “short sale”
(as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our Depositary Shares or (B) hedging transaction, which,
with respect to items (A) and (B), establishes a net short position with respect to the Depositary Shares, during the term of the Purchase
Agreement. The Selling Shareholder has also agreed that neither it nor any entity managed or controlled by it will engage in or effect,
in any manner whatsoever, directly or